Download interactions: TXT MITAB-2.5
| Interaction | Interactor | Experiments | Homologs | Category | Interaction Score |
Confidence |
|---|---|---|---|---|---|---|
|
CYCG
Cyclin G |
1 |
1 |
High-throughput |
0.508 | High |
|
|
Q961D1
Cyclin-K |
1 |
1 |
High-throughput |
0.508 | High |
|
|
Q9VEH1
LD04521p |
1 |
1 |
High-throughput |
0.508 | High |
|
|
Q9VZP3
Cyclin J, isoform A |
1 |
1 |
High-throughput |
0.508 | High |
|
|
E2F2
Transcription factor E2F2 |
1 |
0 |
High-throughput |
0.486 | High |
|
|
CCNA
G2/mitotic-specific cyclin-A |
1 |
0 |
High-throughput |
0.486 | High |
|
|
AKT1
RAC serine/threonine-protein kinase |
1 |
0 |
High-throughput |
0.486 | High |
|
|
PIE
Pineapple eye protein |
1 |
0 |
High-throughput |
0.486 | High |
|
|
M9PH39
histone acetyltransferase |
1 |
1 |
High-throughput |
0.481 | High |
|
|
O76513
Cyclin-H |
1 |
3 |
High-throughput |
0.481 | High |
|
|
Q5U0V6
Cell division cycle 14, isoform B |
1 |
1 |
High-throughput |
0.481 | High |
|
|
SIRT2
NAD-dependent protein deacetylase Sirt2 |
1 |
1 |
High-throughput |
0.481 | High |
|
|
UCHL
Ubiquitin carboxyl-terminal hydrolase |
1 |
0 |
High-throughput |
0.458 | High |
|
|
O17144
Cyclin-H |
1 |
3 |
High-throughput |
0.457 | High |
|
|
Q95TP4
LD33277p |
1 |
1 |
High-throughput |
0.457 | High |
|
|
Q9VLW7
Cell division cycle 14, isoform A |
1 |
1 |
High-throughput |
0.457 | High |
|
|
Q8SYZ4
NAD-dependent protein deacetylase |
1 |
1 |
High-throughput |
0.417 | High |
|
|
A1Z6Z9
Dilute class unconventional myosin, isoform A |
2 |
0 |
High-throughput |
0.305 | High |
|
|
Q9VI02
Uncharacterized protein, isoform A |
1 |
0 |
High-throughput |
0.265 | Low |
|
|
Q9VIF2
GM01519p |
1 |
0 |
High-throughput |
0.265 | Low |
|
|
RG68F
Rho GTPase-activating protein 68F |
1 |
0 |
High-throughput |
0.265 | Low |
|
|
EFHD2
EF-hand domain-containing protein D2 homolog |
1 |
0 |
High-throughput |
0.232 | Low |
|
|
Q9VMH2
Actin-related protein 2/3 complex subunit 4 |
1 |
0 |
High-throughput |
0.232 | Low |
Service provided by Combinatics, Japan
Last updated: 11Aug2025
